Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251669 | 1.00 | P2RY12 (0.47) | P2RY12PRMT5WDR77P2RY2P2RY1 | |
| SCHEMBL7075682 | 0.89 | P2RY12 (0.58) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL7075684 | 0.89 | P2RY12 (0.58) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL7251211 | 0.88 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL5511440 | 0.88 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL25496551 | 0.85 | ADORA3 (0.53) | P2RY12PRMT5WDR77P2RY2P2RY1 | |
| SCHEMBL7065329 | 0.85 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL7065332 | 0.85 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6BMPR1B | |
| SCHEMBL26109581 | 0.85 | PRMT6 (0.46) | P2RY12PRMT5WDR77P2RY2P2RY1 | |
| SCHEMBL7063487 | 0.84 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977767-B1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6849723-B2 | Oligonucleotide analogs having modified dimers | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | COOK PHILLIP DAN (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6420549-B1 | NUCLEOTIDE SEQUENCES FOR USE AS TOOLS IN GENETIC ENGINEERING AND CONTROLLING TRANSLATION | ISIS PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | RNASEL, ADAR, RNGTT | P2RY12 3686/4885PRMT5 998/4885WDR77 1177/4885 |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | P2RY12 4376/4885PRMT5 1736/4885WDR77 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.